VYNE Therapeutics Inc VYNE

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

VYNE Therapeutics Inc (VYNE) Stock: A SWOT Analysis

12d ago, source: newsheater

Company’s 36-month beta value is 1.25.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for VYNE is ...

Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now

1mon ago, source: Hosted on MSN

T he price trend for VYNE Therapeutics Inc. (VYNE) has been bearish lately and the stock has lost 6.7% over the past week. However, the formation of a hammer chart pattern in its last trading ...

VYNE Therapeutics Inc. Common Stock (VYNE)

3y ago, source: Nasdaq

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

VYNE Therapeutics Inc

2d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VYNE Therapeutics Inc

5mon ago, source: CNN

VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial ...

VYNE Therapeutics Inc.

27d ago, source: TheStreet.com

VYNE THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net ...

VYNE Therapeutics Inc.

27d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...